"Betaxolol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
| Descriptor ID |
D015784
|
| MeSH Number(s) |
D02.033.100.624.698.077 D02.033.755.624.698.077 D02.092.063.624.698.077
|
| Concept/Terms |
Betoptic- Betoptic
- Betoptima
- Betaxolol Alcon
- Alcon, Betaxolol
|
Below are MeSH descriptors whose meaning is more general than "Betaxolol".
Below are MeSH descriptors whose meaning is more specific than "Betaxolol".
This graph shows the total number of publications written about "Betaxolol" by people in this website by year, and whether "Betaxolol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Betaxolol" by people in Profiles.
-
Heijl A, Leske MC, Bengtsson B, Bengtsson B, Hussein M. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand. 2003 Jun; 81(3):286-93.
-
Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003 Jan; 121(1):48-56.
-
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct; 120(10):1268-79.